Use of erbb receptor ligands in treating diabetes
CA 2368017 A1 · Owner: Stewart, Timothy Andrew · Inventors: Huang, Xiaojian; Stewart, Timothy Andrew
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention provides methods for treating pancreatic dysfunction particularly diabetes, in mammals using ErbB receptor ligands such as , heregulin, betacellulin, and EGF. Methods of treating such conditions using anti-ErbB receptor agonist antibodies are further provided. The methods of the invention may be performed by direct administration of such therapeutically useful agents to mammals, or alternatively by exposing certain pancreatic , cell types to such agents in vitro and subsequently transplanting the treated cells to a mammal.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 5, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 5, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 5, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.